Skip to main content
. 2024 Aug 30;30(9):e70012. doi: 10.1111/cns.70012

FIGURE 3.

FIGURE 3

Continuous intrathecal injection of Olaparib PROTAC alleviated paclitaxel injection‐induced mechanical allodynia by inhibition of PARP‐1 in rats. (A) Working model of Olaparib PROTAC. (B) The designed Olaparib PROTAC composed of a PARP ligand, a linker and a CRBN ligand. (C) The details of Olaparib PROTAC synthesis. (D) Repeated intrathecal injection of Olaparib PROTAC (1, 5, or 10 μg/10 μL) reversed the decreased PWTs in a dose‐dependent manner. Two‐way ANOVA followed by Bonferroni post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001 versus PINP+vehicle group, n = 7–8 per group. (E) No significant differences of the body weight were observed in PINP+Olaparib PROTAC groups compared to PINP+vehicle group. Two‐way ANOVA followed by Bonferroni post hoc test, p > 0.05, n = 7 per group. (F–H) Continuous intrathecal injection of Olaparib PROTAC inhibited the upregulations of PARP‐1 protein in the PINP rats in a dose‐dependent manner. One‐way ANOVA followed by Bonferroni post hoc test, **p < 0.01, ***p < 0.001 versus corresponding groups, n = 5 per group.